Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two PET radiotracers used in neuroimaging research, particularly for Alzheimer's disease and related neurodegenerative disorders. **11C-PBR28** is a second-generation radioligand that binds to the translocator protein (TSPO), which is upregulated in activated microglia, serving as a marker of neuroinflammation. **18F-florbetaben** is a fluorine-18 labeled stilbene derivative that binds specifically to β-amyloid plaques in the brain, allowing visualization and quantification of amyloid pathology. The combination enables simultaneous or sequential assessment of both amyloid deposition and neuroinflammation within the same subjects using PET imaging. This dual-tracer approach provides complementary information about two key pathological processes in Alzheimer's disease: amyloid accumulation and microglial activation[2][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11C-PBR28 + 18F-Florbetaben.